Home  |  Contact

UniProtKB/Swiss-Prot Q12882: Variant p.Ile543Val

Dihydropyrimidine dehydrogenase [NADP(+)]
Gene: DPYD
Variant information

Variant position:  543
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Isoleucine (I) to Valine (V) at position 543 (I543V, p.Ile543Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In allele DPYD*5.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  543
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1025
The length of the canonical sequence.

Location on the sequence:   LFYTPIDLVDISVEMAGLKF  I NPFGLASATPATSTSMIRRA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LFYTPIDLVDISVEMAGLKFINPFGLASATPATSTSMIRRA

Mouse                         LFYTPVDLVDISVEMAGLRFPNPFGLASATPATSTPMIRRA

Rat                           LFYTPVDLVDISVEMAGLRFPNPFGLASATPATSTPMIRRA

Pig                           LFYTPVDLVDISVEMAGLKFINPFGLASAAPTTSSSMIRRA

Bovine                        LFYTPIDLVDISVEMAALKFTNPFGLASATPTTSSSMIRRA

Zebrafish                     LFHCSIDTVDISVEMCGIKFPNPFGLASAPPTTSAAMIRRA

Caenorhabditis elegans        QFFTPIDEVDISVDMCGVKFENPFGLASAPPTTSGPMCRRA

Slime mold                    NFFTPIDLVDISVEMCGMKFPNPFGLASATPATSAAMIRRS

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 4 – 1025 Dihydropyrimidine dehydrogenase [NADP(+)]
Binding site 550 – 550 FMN
Alternative sequence 174 – 1025 Missing. In isoform 2.


Literature citations

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2); VARIANTS VAL-543 AND ILE-732;

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
Ridge S.A.; Sludden J.; Wei X.; Sapone A.; Brown O.; Hardy S.; Canney P.; Fernandez-Salguero P.; Gonzalez F.J.; Cassidy J.; McLeod H.L.;
Br. J. Cancer 77:497-500(1998)
Cited for: VARIANTS ASN-534 AND VAL-543;

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.
Ridge S.A.; Sludden J.; Brown O.; Robertson L.; Wei X.; Sapone A.; Fernandez-Salguero P.M.; Gonzalez F.J.; Vreken P.; van Kuilenburg A.B.; van Gennip A.H.; McLeod H.L.;
Br. J. Clin. Pharmacol. 46:151-156(1998)
Cited for: VARIANTS ASN-534; VAL-543 AND ILE-732;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.